Agios Pharmaceuticals Stock (NASDAQ:AGIO)
Previous Close
$26.70
52W Range
$23.42 - $62.58
50D Avg
$31.61
200D Avg
$41.28
Market Cap
$1.58B
Avg Vol (3M)
$703.21K
Beta
0.83
Div Yield
-
AGIO Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KALV | KalVista Pharmaceuticals, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| MRSN | Mersana Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| MREO | Mereo BioPharma Group plc |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| MGTX | MeiraGTx Holdings plc |
| ANAB | AnaptysBio, Inc. |
| COGT | Cogent Biosciences, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| ARVN | Arvinas, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| BMRN | BioMarin Pharmaceutical Inc. |